Kiromic Biopharma is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. They are focused on extending the benefits of immunotherapy by leveraging DIAMOND AI (Kiromic Diamond Artificial Intelligence), which is a multi-purpose computational platform that can identify new cancer immunological targets for T-Cells and B-Cells.

Biotechnology

Kiromic Biopharma

Maurizio Chiriva-Internati

Lucia Piccotti

Sarah Madonna

Raquel Dien

Diane Duyen Nguyen

Brian Hungerford

Leonardo Mirandola

Trish Faulkner

Alan Guerrero

Scott Dahlbeck

The Independent Directors at Kiromic Biopharma provide unbiased oversight and guidance to the company's management, ensuring adherence to corporate governance standards and ethical practices. They play a crucial role in strategic decision-making, risk management, and safeguarding shareholder interests, while overseeing the company's commitment to developing advanced immunotherapies and leveraging its DIAMOND AI platform.

Independent Directors

Scientific Research and Operations

Scientific Advisory

Leadership Team

Independent Directors

About

Team members

Other teams at Kiromic Biopharma

Scientific Research and Operations

Scientific Advisory

Leadership Team